Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Nigeria tuberculosis diagnostics market was valued at USD 138.43 Million in 2025 and is expected to grow at a CAGR of 4.40%, reaching USD 212.93 Million by 2035. The market growth is driven by government initiatives and increasing integration of private laboratories into the national diagnostic network.
Compound Annual Growth Rate
4.4%
Value in USD Million
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Tuberculosis (TB) diagnostics refers to the range of laboratory tests, molecular assays, imaging techniques, and clinical procedures used to detect Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, determine the presence and extent of infection, and identify drug resistance to guide appropriate treatment. The market was valued at USD 138.43 Million in 2025, driven by the high burden of undiagnosed and underdiagnosed tuberculosis, expansion of molecular diagnostic testing, government-led TB case-finding initiatives, and international funding for diagnostic infrastructure.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Expansion of decentralized molecular testing to improve tuberculosis diagnostic access |
In March 2026, Nigeria announced the nationwide rollout of over 1,000 Pluslife Mini Dock devices, alongside expanding GeneXpert and Truenat networks. |
|
Market Restraints |
Inadequate domestic funding and shortages of essential diagnostic supplies |
In June 2026, reports highlighted USD 54 million in pending government counterpart funding and GeneXpert cartridge shortages across Nigerian facilities. |
|
Market Opportunities |
Expansion of near-point-of-care molecular testing and community-based screening |
In June 2026, the Global Fund selected Nigeria among 13 countries for nearly 3 million portable molecular TB tests. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Expansion of Decentralized Molecular Testing to Enhance the Market Demand
The expansion of decentralized molecular testing is improving access to tuberculosis diagnosis across underserved communities in Nigeria. In March 2026, the Federal Government announced the nationwide deployment of over 1,000 Pluslife Mini Dock near-point-of-care diagnostic devices, alongside expanding GeneXpert and Truenat networks. These initiatives are strengthening diagnostic accessibility and supporting earlier TB detection.
Inadequate and Unpredictable Funding for Diagnostic Consumables to Limit the Market Value
Insufficient domestic healthcare funding and dependence on external assistance are restricting the availability of essential tuberculosis diagnostic supplies in Nigeria. In June 2026, the Guardian Nigeria reported that the government had yet to release USD 54 million in counterpart funding for TB programmes. The report also highlighted GeneXpert cartridge shortages across monitored facilities. Such funding gaps and supply disruptions can delay testing, reduce diagnostic accessibility, and constrain the expansion of tuberculosis diagnostic services across the country.
Development of Near-Point-of-Care Molecular Testing and Community-Based Screening to Improve the Market Growth
The expansion of decentralized molecular testing is creating opportunities to improve tuberculosis diagnosis across underserved communities in Nigeria. In June 2026, the Global Fund selected Nigeria among 13 countries for nearly 3 million near-point-of-care molecular TB tests. Subsequently, in August 2026, Stop TB Partnership Nigeria outlined a RADxAR-TB implementation plan covering 250 facilities across 200 local government areas in 31 states. These initiatives are expected to improve diagnostic accessibility and support demand for molecular testing technologies.
The market is witnessing several key trends, including the growing adoption of decentralized molecular testing, AI-enabled screening technologies, and digitally integrated TB surveillance systems.
Shift Towards Decentralized Molecular Testing and AI-Enabled Digital Screening to Enhance the Market
The market is witnessing a shift towards decentralized molecular testing and AI-enabled digital screening, improving access to early TB detection. In March 2025, Nigeria's Federal Government announced the deployment of portable digital X-ray equipment and expansion of AI-enabled surveillance. Subsequently, in March 2026, the Ministry of Health initiated the rollout of over 1,000 Pluslife Mini Dock near-point-of-care diagnostic devices and strengthened electronic reporting systems. These developments are expanding diagnostic accessibility and supporting decentralized TB testing across Nigeria.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Molecular Diagnostics are most Likely to Lead the Market by Diagnostics
Molecular diagnostics are gaining importance in the market, supported by the expansion of rapid testing infrastructure and increasing demand for early disease detection. According to the WHO Regional Office for Africa (2026), Nigeria has scaled up GeneXpert testing nationwide, improving access to rapid, bacteriologically confirmed diagnosis. These platforms offer greater diagnostic sensitivity than smear microscopy, faster results and opportunities for drug-resistance detection, supporting continued investment in instruments and recurring test consumables.
The key features of the market report include strategic initiatives by leading players. The major companies in the market are as follows:
Becton, Dickinson and Company is a global medical technology company specializing in diagnostic systems, laboratory instruments and clinical testing solutions. Its portfolio includes microbiology products, specimen collection systems and molecular diagnostic technologies. The company supports tuberculosis detection through laboratory infrastructure, automated diagnostic workflows and solutions that strengthen infectious disease testing capabilities across healthcare systems.
FUJIFILM Holdings Corporation operates across healthcare, medical imaging, life sciences and diagnostic technologies. Its healthcare portfolio includes digital radiography, medical imaging systems and diagnostic solutions. The company contributes to tuberculosis detection through chest imaging technologies, supporting pulmonary screening, disease identification and clinical assessment, particularly in healthcare facilities seeking improved diagnostic efficiency and imaging capabilities.
Molbio Diagnostics is an Indian molecular diagnostics company specializing in portable, point-of-care testing platforms. Its Truenat system provides real-time PCR-based detection of tuberculosis and rifampicin resistance. The company focuses on decentralized molecular testing, enabling faster diagnosis in peripheral healthcare facilities and expanding access to tuberculosis diagnostics across resource-limited settings and emerging markets.
Qure.ai Technologies develops artificial intelligence-powered medical imaging solutions for automated interpretation of radiological scans. Its qXR platform analyses chest X-rays to identify abnormalities associated with pulmonary tuberculosis, supporting screening, triage and early detection. The company collaborates with healthcare organisations and public health programmes to expand AI-assisted tuberculosis screening, particularly in high-burden and resource-constrained settings.
Other key players in the market include Abbott, Qiagen N.V., Cepheid, Eiken Chemical Co., Ltd., F. Hoffmann-La Roche Ltd., and Hain Lifescience GmbH.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnostics
The market is supported by the expansion of rapid molecular testing, particularly GeneXpert-based platforms, alongside established microscopy and culture facilities. Government-led TB control programmes, increased screening of vulnerable populations, and international funding are strengthening diagnostic infrastructure. Rising demand for rapid rifampicin-resistance detection is also supporting advanced diagnostic adoption
Market Breakup by Disease Type
Pulmonary tuberculosis accounts for a substantial share of diagnostic demand because it represents the most common form of active TB and remains the primary driver of community transmission. Extrapulmonary testing is required to identify infections affecting organs beyond the lungs, while latent TB testing supports preventive treatment programmes among high-risk populations.
Market Breakup by End User
Hospitals represent an important end-user segment owing to their role in patient screening, clinical diagnosis, treatment initiation and management of complicated TB cases. Diagnostic laboratories support confirmatory testing through molecular assays, microscopy and culture-based techniques. Research laboratories contribute to diagnostic development, drug-resistance surveillance and epidemiological investigations, strengthening Nigeria's overall TB testing infrastructure.
This report is developed through a structured mixed-methods research approach combining secondary research, market assessment, and data validation:
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostics |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.